| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 38,400 | 40,000 | 12:55 | |
| 38,600 | 40,200 | 12:58 |
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| Mo | AKTIONÄR-Tipp Cytokinetics hebt ab - die Hintergründe | Biotech-Aktien stehen wieder höher in der Gunst der Anleger. In AKTIONÄR-Ausgabe 35/25 wurden vier aussichtsreiche Werte vorgestellt, die derzeit besonders aussichtsreich sind. Mit von der Partie: Cytokinetics.... ► Artikel lesen | |
| So | Cytokinetics, Incorporated: Cytokinetics Presents New Data Related to Aficamten at the European Society of Cardiology Congress 2025 | ||
| Sa | Cytokinetics posts detailed Phase 3 data for lead asset in hypertrophic cardiomyopathy | ||
| Sa | Cytokinetics And The 'Provocative Conversation' That Could Rewrite Heart Disease | ||
| Sa | Cytokinetics, Incorporated: Cytokinetics Announces Primary Results from MAPLE-HCM Presented at the European Society of Cardiology Congress 2025 and Published in The New England Journal Of Medicine | Positive Trial Demonstrates Superiority of Aficamten to Standard-of-Care Beta-Blocker Metoprolol Primary Endpoint Result Consistent Across All Prespecified Subgroups Company to Host Investor Event... ► Artikel lesen |
